Since COX-2 has been also associated to pancreatic cancer cell proliferation [28] or tumor growth [29]–[31], we hypothesized that COX-2 overexpression may also be induced in PDAC when treated with HDAC inhibitors, leading to reduced efficiency and hence therapeutic failure. Here, HDAC9 is linked to pancreatic neoplasm.